State of Wyoming Purchases 1,490 Shares of BioLife Solutions, Inc. $BLFS

State of Wyoming raised its position in BioLife Solutions, Inc. (NASDAQ:BLFS) by 353.1% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,912 shares of the medical equipment provider’s stock after purchasing an additional 1,490 shares during the period. State of Wyoming’s holdings in BioLife Solutions were worth $44,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in BLFS. T. Rowe Price Investment Management Inc. bought a new stake in shares of BioLife Solutions during the 1st quarter worth $30,789,000. Point72 Asset Management L.P. purchased a new position in shares of BioLife Solutions during the fourth quarter valued at about $11,113,000. Millennium Management LLC boosted its stake in BioLife Solutions by 49.1% during the fourth quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider’s stock worth $29,733,000 after acquiring an additional 377,111 shares in the last quarter. Invesco Ltd. boosted its stake in BioLife Solutions by 9.6% during the first quarter. Invesco Ltd. now owns 3,551,054 shares of the medical equipment provider’s stock worth $81,106,000 after acquiring an additional 311,585 shares in the last quarter. Finally, Palisade Capital Management LP boosted its stake in BioLife Solutions by 13.7% during the first quarter. Palisade Capital Management LP now owns 947,085 shares of the medical equipment provider’s stock worth $21,631,000 after acquiring an additional 113,937 shares in the last quarter. 93.24% of the stock is owned by institutional investors.

BioLife Solutions Stock Performance

NASDAQ BLFS opened at $26.49 on Thursday. BioLife Solutions, Inc. has a one year low of $19.10 and a one year high of $29.55. The company has a market capitalization of $1.27 billion, a price-to-earnings ratio of -220.73 and a beta of 1.78. The company’s 50-day simple moving average is $23.36 and its two-hundred day simple moving average is $23.29.

BioLife Solutions (NASDAQ:BLFS) last released its quarterly earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.31). BioLife Solutions had a negative net margin of 5.39% and a positive return on equity of 0.16%. The firm had revenue of $25.42 million during the quarter, compared to the consensus estimate of $23.71 million. BioLife Solutions has set its FY 2025 guidance at EPS. Equities analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Insider Activity at BioLife Solutions

In other BioLife Solutions news, CMO Todd Berard sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The shares were sold at an average price of $25.53, for a total transaction of $255,300.00. Following the transaction, the chief marketing officer owned 124,618 shares in the company, valued at approximately $3,181,497.54. This represents a 7.43% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, major shareholder Casdin Partners Master Fund, L sold 500,000 shares of the company’s stock in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $24.40, for a total transaction of $12,200,000.00. Following the transaction, the insider owned 6,707,165 shares in the company, valued at $163,654,826. The trade was a 6.94% decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 1,016,359 shares of company stock worth $23,902,747. 2.20% of the stock is owned by insiders.

Wall Street Analyst Weigh In

BLFS has been the topic of several analyst reports. Wall Street Zen downgraded shares of BioLife Solutions from a “hold” rating to a “sell” rating in a research note on Wednesday, May 21st. Stephens started coverage on shares of BioLife Solutions in a report on Tuesday, July 22nd. They set an “overweight” rating and a $30.00 target price for the company. Zacks Research raised shares of BioLife Solutions to a “strong-buy” rating in a research note on Monday, August 11th. Finally, HC Wainwright restated a “buy” rating and set a $32.00 target price (up previously from $30.00) on shares of BioLife Solutions in a research report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $31.29.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.